{"name":"Xanthus Pharmaceuticals, Inc.","slug":"xanthus-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amonafide L-Malate","genericName":"Amonafide L-Malate","slug":"amonafide-l-malate","indication":"Acute myeloid leukemia","status":"phase_2"}]}],"pipeline":[{"name":"Amonafide L-Malate","genericName":"Amonafide L-Malate","slug":"amonafide-l-malate","phase":"phase_2","mechanism":"Amonafide L-Malate is a quinazoline derivative that intercalates DNA, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells.","indications":["Acute myeloid leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPNi1FY2dRa1RBTHNhWGFBQk8zS0xvU2swRVF0Q21sWmpEZWhSMzZFc0loUHJ4Ynl6bDBBRDNtSWp1S0Z1clhkNHU0LWNxSTVhWXY0U19ET1NuSjkwczA2SW5RVVU4aGtGdHRYTU5nZExmcmpzNlZtYVZHX1ZyS1czWXpMeF85M0lvUV9rZnZZV08xTlBZenJXZlpSSzBJRnFlR1NpaTU4QkRHOGV1c2ZSbkY0OFZkZmVlNnhmbTlXem1VTGt0MFF3Rw?oc=5","date":"2022-05-03","type":"pipeline","source":"Business Wire","summary":"Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer - Business Wire","headline":"Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}